公开(公告)号：US20180338925A1

公开(公告)日：2018-11-29

申请号：US15755374

申请日：2016-08-23

Applicant: RUSAN PHARMA LIMITED

Inventor： Navin SAXENA ,  Kunal SAXENA

IPC: A61K9/20 ,  A61K9/00 ,  A61K31/485 ,  A61P3/04 ,  A61P25/00

CPC classification number: A61K9/2027 ,  A61K9/0024 ,  A61K9/2013 ,  A61K9/204 ,  A61K31/485 ,  A61P3/04 ,  A61P25/00

Abstract: The invention discloses naltrexone implantable tablets which are devoid of metal salts and corticosteroids, and which provide consistent and controlled amount of naltrexone for 3 months or more; also disclosed is methods of treatment comprising the implants and methods of sterilization of the implants.

公开(公告)号：US20140364612A1

公开(公告)日：2014-12-11

申请号：US14302159

申请日：2014-06-11

Applicant: RUSAN PHARMA LIMITED

Inventor： Navin Satyapal SAXENA ,  Kunal SAXENA ,  Kaushik Babubhai SATA

IPC: C07D489/12

CPC classification number: C07D489/12 ,  C07D489/02

Abstract: There is provided an efficient industrial process for the preparation of 21-cyclopropyl-7α-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydro-oripavine, i.e. buprenorphine of Formula-I in high yield and purity, with enhanced safety and eco-friendly norms. The invention further relates to an improved process for preparation of intermediates thereof in high yield and purity.

Abstract translation: 提供了制备21-环丙基-7α-（2-羟基-3,3-二甲基-2-丁基）-6,14-内 - 乙酰胺-6,7,8,14-四氢的有效工业方法 - 高磷脂，即具有高产率和纯度的式I的丁丙诺啡，具有增强的安全性和环保标准。 本发明还涉及以高产率和纯度制备其中间体的改进方法。

公开(公告)号：US10507184B2

公开(公告)日：2019-12-17

申请号：US15755374

申请日：2016-08-23

Applicant: RUSAN PHARMA LIMITED

Inventor： Navin Saxena ,  Kunal Saxena

IPC: A61K9/20 ,  A61P25/00 ,  A61K31/485 ,  A61P3/04 ,  A61K9/00

Abstract: The invention discloses naltrexone implantable tablets which are devoid of metal salts and corticosteroids, and which provide consistent and controlled amount of naltrexone for 3 months or more; also disclosed is methods of treatment comprising the implants and methods of sterilization of the implants.

公开(公告)号：US08981097B2

公开(公告)日：2015-03-17

申请号：US14302159

申请日：2014-06-11

Applicant: Rusan Pharma Limited

Inventor： Navin Satyapal Saxena ,  Kunal Saxena ,  Kaushik Babubhai Sata

IPC: C07D489/12 ,  C07D489/02

CPC classification number: C07D489/12 ,  C07D489/02

Abstract: There is provided an efficient industrial process for the preparation of 21-cyclopropyl-7α-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydro-oripavine, i.e. buprenorphine of Formula-I in high yield and purity, with enhanced safety and eco-friendly norms. The invention further relates to an improved process for preparation of intermediates thereof in high yield and purity.

Abstract translation: 提供了制备21-环丙基-7α-（2-羟基-3,3-二甲基-2-丁基）-6,14-内 - 乙酰胺-6,7,8,14-四氢的有效工业方法 - 高磷脂，即具有高产率和纯度的式I的丁丙诺啡，具有增强的安全性和环保标准。 本发明还涉及以高产率和纯度制备其中间体的改进方法。